CytoCure LLC is an early-stage biopharmaceutical company founded on a novel platform technology to develop anti-cancer drugs that
will make therapeutic cancer vaccines more effective. When combined with cancer immunotherapy, CytoCure's drugs
will enhance patients' ability to recognize and destroy their own malignant tumors.
CytoCure scientists have discovered a process
by which tumor cells lose expression of genes encoding immune targets. This process of "antigen silencing"
is a common finding among tumors. CytoCure scientists have shown that the loss of these antigens is often due
to reversible gene regulation. Proprietary CytoCure technology is based on overcoming tumor-produced factors that induce loss
of tumor antigens, thus assuring that the tumor cells continue to express the antigenic structures that will allow the immune
response to destroy all tumor cells in the tumor mass.
Since the loss of tumor associated antigens currently
represents a significant limitation to the success of cancer vaccines, the re-introduction and/or up-regulation of antigen
expression will be a necessary adjunct to these therapies. Although the anti-tumor immune response can be markedly
enhanced by strategic vaccination, the ability to destroy the tumor is dependent on the continued expression of the
target antigen. CytoCure's technology provides for a platform to
assure the continued expression and regulation of "antigen silencing" to enhance immunotherapeutic treatment of
The cancer therapies envisioned by CytoCure's first-line
of therapeutics will require combining two components: (1) The antigen augmentation drug (i.e. a drug that increases
antigen expression) which CytoCure has developed and identified; and (2) An Immunotherapeutic Intervention,
such as adoptive immunotherapy. To date, CytoCure has identified biologically available small molecule leads
and the cytokine, interferon-beta, that is already approved for the treatment of Multiple Sclerosis, and has produced tumor-specific
cells that can be used in immunotherapy.